Zini Jean-Marc, Tobelem Gérard
Service d'angio-hématologie, Hôpital Lariboisière, 2, rue Ambroise-Paré, 75010 Paris.
Bull Cancer. 2007 Jul;94 Spec No:S241-6.
Angiogenesis plays an important role in the progression of tumors. This relationship has been described in several hematologic malignancies. Vascular endothelial growth factor and basic fibroblast growth factor are predictors of poor prognosis in leukemia and non Hodgkin's lymphoma. Bone marrow microvessels were found increased in multiple myeloma, but also in lymphoma and in acute lymphoblastic leukemia. Microvessel density is correlated with decreased survival in myeloma patients and relapse or resistance to chemotherapy in lymphoma. New drugs with antiangiogenic activity such as bevacizumab (binding and inactivation of VEGF) or VEGF-tyrosine kinase inhibitors have shown promising results in phase 1 trials. It will therefore be a future challenge to integrate anti-angiogenesis agents in currently existing treatment protocols to improve the outcome of therapy.
血管生成在肿瘤进展中起重要作用。这种关系已在多种血液系统恶性肿瘤中得到描述。血管内皮生长因子和碱性成纤维细胞生长因子是白血病和非霍奇金淋巴瘤预后不良的预测指标。在多发性骨髓瘤中发现骨髓微血管增加，在淋巴瘤和急性淋巴细胞白血病中也有发现。微血管密度与骨髓瘤患者生存率降低以及淋巴瘤化疗复发或耐药相关。具有抗血管生成活性的新药，如贝伐单抗（结合并灭活VEGF）或VEGF酪氨酸激酶抑制剂，在1期试验中已显示出有前景的结果。因此，将抗血管生成药物整合到现有治疗方案中以改善治疗结果将是未来的一项挑战。
